Coagulopathy in two patients with cystic fibrosis treated with ciprofloxacin  by Moore, Gillian C. et al.
6 (2007) 209–211
www.elsevier.com/locate/jcfJournal of Cystic FibrosisCoagulopathy in two patients with cystic fibrosis treated
with ciprofloxacin
Gillian C. Moore a,⁎, Jan Redfern a, Caroline R. Shiach b, Kevin Webb a, Andrew M. Jones a
a Manchester Adult Cystic Fibrosis Unit, North West Lung Centre, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK
b Department of Haematology, Wythenshawe Hospital, Southmoor Road, Wythenshawe, Manchester, M23 9LT, UK
Received 26 April 2006; received in revised form 13 August 2006; accepted 18 August 2006
Available online 12 October 2006Abstract
We report two cases of prolonged blood clotting times as demonstrated by a raised international normalised ratio and elevated activated
partial thromboplastin time in patients with cystic fibrosis taking ciprofloxacin. The potential mechanisms of a coagulopathy of this picture as
an adverse drug reaction with ciprofloxacin are discussed along with the possible clinical consequences for patients with cystic fibrosis.
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Ciprofloxacin is a commonly prescribed oral antibiotic
for patients with cystic fibrosis (CF) due to its efficacy in
treatment of Pseudomonas aeruginosa infection [1,2].
Ciprofloxacin is documented to induce a coagulopathy,
namely, a raised international normalised ratio (INR), in
patients taking warfarin [3]; however, it has been reported
that at the usual oral ciprofloxacin dose of 500 mg twice
daily this effect is usually not significant [4]. The proposed
mechanism of this action is by inhibition of the IA2 isoform
of cytochrome P450 enzyme [5]. There are no published
reports of a raised INR in patients taking ciprofloxacin who
are not on anti-coagulant medication.
2. Case reports
2.1. Case 1
A 29-year-old woman with CF and chronic P. aeruginosa
infection was admitted with features of distal intestinal⁎ Corresponding author. Tel.: +44 161 291 2154; fax: +44 161 291 2080.
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doi:10.1016/j.jcf.2006.08.002obstruction syndrome. She had a past history of a right
internal jugular venous thrombosis related to the insertion of
a permanent venous access device and a right-sided common
femoral deep vein thrombosis secondary to a temporary
venous access line. On the advice of the haematology team,
she was using 1.5 mg/kg subcutaneous enoxaparin daily as
she had difficulty complying with the regular monitoring of
INR required with previous warfarin therapy.
During the admission her spirometric values worsened
and she was treated with intravenous (IV) ciprofloxacin
400 mg twice daily and nebulised tobramycin.
Two days after commencing ciprofloxacin her INR was
3.4 compared to a baseline INR of 1.0. This was confirmed
on sending a repeat sample. In addition, the APTTwas 41.2 s
compared to a baseline of 22.1 s. Renal and synthetic liver
function tests were normal throughout the admission. The IV
ciprofloxacin was changed to IV ceftazidime. Twenty-four
hours later, her INR had settled to baseline values (1.3) and
her APTT was back within the normal range (26.0 s).
Enoxaparin was continued in view of her prothrombotic
history and she was discharged home 5 days later after her
abdominal symptoms improved. The possibility of a raised
INR secondary to ciprofloxacin therapy was reported via a
“yellow card” system to the Medicines and Healthcare
Products Regulatory Agency (MHRA).ed by Elsevier B.V. All rights reserved.
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An 18-year-old womanwith CF and chronicP. aeruginosa
infection presented to outpatients with a 1-week history of a
coryzal illness and mildly increased dyspnoea. She was given
a course of oral ciprofloxacin 1 g bd and rifampicin 300 mg
bd. She was not taking any anticoagulant drugs and had
previously tolerated this antibiotic combination without
problems.
Five days after starting ciprofloxacin and rifampicin she
re-presented with vomiting. Blood tests revealed a markedly
raised urea and creatinine (urea 17.6 mmol/l, creatinine
768 μmol/l), an INR of 2.6 and APTT of 45.1 s. These
compared to baseline values of urea 3.9mmol/l and creatinine
83 μmol/l taken 8 weeks previously. Her liver function tests
were normal, paracetamol levels were undetectable and she
was haemodynamically stable. There were no other clinical
signs of sepsis and no organisms grown on repeated sets of
blood cultures.
Ciprofloxacin and rifampicin were discontinued. She was
seen by the nephrologists who felt that her worsening renal
function represented interstitial nephritis secondary to
ciprofloxacin toxicity rather than pre-renal failure.
Over the next week, she made a good clinical im-
provement and was monitored with daily measurements of
coagulation and urea and electrolytes (Fig. 1). Her INR was
normal (1.0) at discharge. At discharge urea was 15.1 mmol/
l and creatinine 265 μmol/l. These slowly returned to base-
line 3 weeks after discharge. Her APTT returned to values
within the normal range 72 h after the antibiotics were
terminated.
The incident was reported to MHRA as a complication of
ciprofloxacin and rifampicin therapy.Fig. 1. Trends in creatinine3. Discussion
In both cases, there was an increase in both the INR and
APTT that coincided with starting ciprofloxacin that was
reversible on discontinuation of the drug. This is an
important side effect and has not previously been reported
in patients who are not taking warfarin.
On reviewing reporting of adverse drug reactions for
ciprofloxacin to the MHRA [6], there are a total of 5643
adverse drug reactions reported for ciprofloxacin of which
70 were fatal. Amongst these are 34 reported cases of acute
renal failure of which 3 were fatal. Four cases of acquired
coagulopathy are reported, none of which were fatal.
The aetiology of this picture of coagulopathy noted with
ciprofloxacin is unknown. A case of factor VIII inhibitor
possibly caused by ciprofloxacin has been reported [7], as has
acquired transitory von Willebrand syndrome [8] and a case
of prolonged bleeding time [9]. Two incidents of acquired
factor V inhibition and antiphospholipid antibodies after
treatment with ciprofloxacin have been reported [10].
Patients with CF tend to receive higher doses of cipro-
floxacin than other patients due to enhanced activity of certain
cytochrome P450 enzymes and increased renal clearance [11],
and these increased doses could increase the chance of adverse
drug reactions. It is also possible that both patients had
borderline low levels of vitamin K due to exocrine pancreatic
insufficiency related to cystic fibrosis [12] and possibly that
ciprofloxacin further reduced gastrointestinal vitamin K
absorption leading to a temporary vitamin K-deficient state
and explaining the raised INR and APTT. We postulate that
selective deficiencies of vitamin K-dependent clotting factors
were a possible causative link for the coagulopathy and that
factor VII in particular is implicated due to the relatively quickand INR in case 2.
211G.C. Moore et al. / Journal of Cystic Fibrosis 6 (2007) 209–211return of INR to baseline in both cases after stopping
ciprofloxacin.
In both patients, there were no adverse clinical conse-
quences from the temporary prolongation of the INR.
However, massive haemoptysis is a recognised complication
of CFwith an average annual incidence of just under 1% and a
lifetime incidence of 4.1% [13]. In patients with haemoptysis,
an unexpected coagulopathy could have significant clinical
consequences.
Unfortunately, in neither case, clotting factor assays were
undertaken. If a similar effect is seen in the future,
measurement of clotting factor levels would be helpful.
In conclusion, we present two cases of a prolonged INR
and APTT in patients with CF on ciprofloxacin therapy. In
one case, the patient was on enoxaparin in view of a previous
prothrombotic history and in the other case the patient also
developed an interstitial nephritis. These co-morbid factors
may have predisposed the patients to developing the
coagulopathy that we have reported. However, in the first
case, the significant rise in INR cannot be explained by long-
term enoxaparin therapy and in the second case the nephritis
would not explain the marked prolongation of APTT and
INR. In addition, the coagulopathy reversed promptly in
both cases when the ciprofloxacin was stopped.
The aetiology of this mechanism is unclear and would
benefit from further investigation. Due to the frequency of
ciprofloxacin prescription, it is important to be aware of this
potential adverse drug reaction in clinical practice in caring
for patients with CF. We would encourage reporting further
similarly observed reactions through MRHA in addition to
measurement of clotting factor levels to enable further details
regarding the aetiology of this effect to be obtained.
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